Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation.

Bocci, G; Tuccori, M; Emmenegger, U; Liguori, V; Falcone, A; Kerbel, R S; Del Tacca, M

Bocci, G; Tuccori, M; Emmenegger, U; Liguori, V; Falcone, A; Kerbel, R S; Del Tacca, M.

Affiliation

Bocci G; Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies, University of Pisa, Via Roma, Pisa, Italy. g.bocci@med.unipi.it

Ann Oncol ; 16(8): 1243-52, 2005 Aug.

Article in En | MEDLINE | ID: mdl-15905308

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/economics; Breast Neoplasms/drug therapy; Breast Neoplasms/economics; Administration, Oral; Breast Neoplasms/secondary; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Cyclophosphamide/administration & dosage; Cyclophosphamide/economics; Drug Costs; Economics, Pharmaceutical; Humans; Infusions, Intravenous; Methotrexate/administration & dosage; Methotrexate/economics; Palliative Care

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Health_economic_evaluation Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2005 Document type: Article Affiliation country: Italy Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links